These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 6355048)

  • 1. Pharmacokinetics of acyclovir after intravenous and oral administration.
    de Miranda P; Blum MR
    J Antimicrob Chemother; 1983 Sep; 12 Suppl B():29-37. PubMed ID: 6355048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of acyclovir pharmacokinetic disposition in adults and children.
    Blum MR; Liao SH; de Miranda P
    Am J Med; 1982 Jul; 73(1A):186-92. PubMed ID: 7048911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.
    Tod M; Lokiec F; Bidault R; De Bony F; Petitjean O; Aujard Y
    Antimicrob Agents Chemother; 2001 Jan; 45(1):150-7. PubMed ID: 11120958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefetamet pivoxil clinical pharmacokinetics.
    Blouin RA; Stoeckel K
    Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis.
    Shah GM; Winer RL; Krasny HC
    Am J Kidney Dis; 1986 Jun; 7(6):507-10. PubMed ID: 3717158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acyclovir kinetics after intravenous infusion.
    de Miranda P; Whitley RJ; Blum MR; Keeney RE; Barton N; Cocchetto DM; Good S; Hemstreet GP; Kirk LE; Page DA; Elion GB
    Clin Pharmacol Ther; 1979 Dec; 26(6):718-28. PubMed ID: 227639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.
    Larsson R; Erlanson P; Bodemar G; Walan A; Bertler A; Fransson L; Norlander B
    Br J Clin Pharmacol; 1982 Feb; 13(2):163-70. PubMed ID: 7059413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis.
    Burgess ED; Gill MJ
    J Clin Pharmacol; 1990 Nov; 30(11):997-1000. PubMed ID: 2243158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyclovir (Zovirax) pharmacokinetics in Quaker parakeets, Myiopsitta monachus.
    Norton TM; Kollias GV; Clark CH; Gaskin J; Wilson RC; Coniglario J
    J Vet Pharmacol Ther; 1992 Sep; 15(3):252-8. PubMed ID: 1433488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans.
    Laskin OL; de Miranda P; King DH; Page DA; Longstreth JA; Rocco L; Lietman PS
    Antimicrob Agents Chemother; 1982 May; 21(5):804-7. PubMed ID: 7103460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
    Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
    Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
    Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species differences in the disposition of acyclovir.
    de Miranda P; Krasny HC; Page DA; Elion GB
    Am J Med; 1982 Jul; 73(1A):31-5. PubMed ID: 7102710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A515U: a prodrug of acyclovir with increased oral bioavailability.
    Rees PJ; Selby P; Prentice HG; Whiteman PD; Grant DM
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():215-22. PubMed ID: 3793661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals.
    Whitley RJ; Blum MR; Barton N; de Miranda P
    Am J Med; 1982 Jul; 73(1A):165-71. PubMed ID: 7102700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans.
    Laskin OL; Longstreth JA; Saral R; de Miranda P; Keeney R; Lietman PS
    Antimicrob Agents Chemother; 1982 Mar; 21(3):393-8. PubMed ID: 7103443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
    Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.